[Form 4] Integra LifeSciences Holdings Insider Trading Activity

Rhea-AI Filing Summary

Integra LifeSciences (IART) Form 4: Director Stuart Essig reported multiple internal transfers of common stock in August 2025. On August 14, 2025 he transferred 200,000 shares to a grantor trust for which his spouse is trustee and received assets of equal fair market value. The same date shows a 200,000-share acquisition entry at $13.62 and a 200,000-share disposition at $13.62 reflecting the trust transfer. Prior to that, on August 8, 2025, 180,080 shares were distributed to Essig from GRAT E as an annuity payment and 500,000 shares were distributed from GRAT F as an annuity payment; GRAT F was then terminated because remaining shares were insufficient to satisfy the annuity obligation. Following the reported transactions, the filings list 1,152,236 shares beneficially owned directly and various indirect holdings through trusts (including 219,920 by GRAT E and 213,115 by a family trust).

Positive

• Transactions were internal transfers to related trusts rather than open-market disposals, preserving control within related parties
• Form 4 fully discloses the grantor trust transfers and GRAT distributions, providing transparency on insider ownership changes

Negative

• GRAT F terminated after a 500,000-share distribution because remaining shares were insufficient to satisfy the annuity, indicating a material reduction in that vehicle
• Significant share movement (500,000 and 180,080 shares) alters the mix of direct and indirect ownership and may change future share voting patterns

Insights

Financial Analyst

TL;DR: Insider moved significant share blocks among related trusts and personal holdings; transactions appear estate-planning driven, not open-market trading.

The Form 4 shows material intra-family and trust transfers rather than market sales. Key events are the 500,000-share distribution from GRAT F (which then terminated) and the 180,080-share distribution from GRAT E. These movements change the reporting mix of direct versus indirect ownership but do not explicitly indicate third-party dispositions. For investors, the primary relevance is a change in ownership reporting and potential future availability of shares as trusts are settled; no revenue, earnings, or operational data are affected by these entries.

Corporate Governance Expert

TL;DR: Transactions reflect structured estate/planning actions; termination of a GRAT following partial satisfaction is notable for ownership structure.

The filings document transfers to a grantor trust (200,000 shares) and annuity distributions from two GRATs, including the termination of GRAT F after a 500,000-share distribution due to insufficient remaining assets. Signatures include an attorney-in-fact, indicating authorized filing. From a governance perspective, these are standard trustee and grantor actions that alter beneficial ownership reporting and may affect future voting and disclosure timelines. There is no indication of regulatory issues or third-party trades in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ESSIG STUART

(Last) (First) (Middle)

1100 CAMPUS ROAD

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2025		J		200,000	D	$13.62	1,152,236(1)(2)(3)	D
Common Stock								219,920(2)	I	By GRAT E
Common Stock								0(3)	I	By GRAT F
Common Stock								213,115	I	By Family Trust
Common Stock	08/14/2025		J		200,000	A	$13.62	200,000	I	By Grantor Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On August 14, 2025, the reporting person transferred 200,000 shares of common stock to a grantor trust for which his spouse is the trustee. In exchange for the shares, the trust transferred assets to the reporting person with a fair market value equal to the transferred shares. The transfer of shares to the trust resulted in a decrease in the number of shares the reporting person beneficially owns directly and a corresponding increase in the number of shares the reporting person beneficially owns indirectly through the trust.

2. On August 8, 2025, in accordance with the provisions of a grantor retained annuity trust ("GRAT E"), 180,080 shares of common stock were distributed from GRAT E to the reporting person as an annuity payment in accordance with the terms of GRAT E.

3. On August 8, 2025, in accordance with the provisions of a grantor retained annuity trust ("GRAT F"), 500,000 shares of common stock were distributed from GRAT F to the reporting person as an annuity payment in accordance with the terms of GRAT F. The amount of shares available for distribution were insufficient to satisfy the full amount of the annuity payment obligation and so GRAT F was terminated, in accordance with the terms of GRAT F, following the completion of the foregoing distribution.

Remarks:

	/s/ Lesha Shinn; Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Stuart Essig report on the IART Form 4?

The Form 4 reports a 200,000-share transfer to a grantor trust on August 14, 2025, a 180,080-share distribution from GRAT E on August 8, 2025, and a 500,000-share distribution from GRAT F on August 8, 2025 followed by termination of GRAT F.

How many shares does Essig beneficially own directly after these transactions?

The filing lists 1,152,236 shares beneficially owned directly following the reported transactions.

Were any shares sold on the open market according to this Form 4?

No open-market sales are reported; the entries reflect transfers and annuity distributions between the reporting person and related trusts.

Why was GRAT F terminated according to the filing?

GRAT F was terminated because the amount of shares available for distribution were insufficient to satisfy the full annuity payment obligation after the 500,000-share distribution.

Who signed the Form 4 for Stuart Essig?

The form was signed by Lesha Shinn, attorney-in-fact, on August 18, 2025.